808 results on '"Acosta, Edward P."'
Search Results
2. Predictors of HIV rebound differ by timing of antiretroviral therapy initiation
3. Population Pharmacokinetic Modeling of Dolutegravir to Optimize Pediatric Dosing in HIV-1-Infected Infants, Children, and Adolescents.
4. HIV post-treatment controllers have distinct immunological and virological features
5. Bridging dolutegravir clinical viral response across doses and formulations using model-based exposure–response analysis in pediatrics
6. Differential distribution of ivacaftor and its metabolites in plasma and human airway epithelia
7. Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093): results of an open-label, phase 1–2 trial
8. Time to Viral Rebound After Interruption of Modern Antiretroviral Therapies
9. Optimizing Dolutegravir Initiation in Neonates Using Population Pharmacokinetic Modeling and Simulation
10. A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer
11. Time to Viral Rebound After Interruption of Modern Antiretroviral Therapies.
12. Pharmacokinetics and safety of maraviroc in neonates.
13. Pharmacokinetics, safety, and tolerability of dispersible and immediate-release abacavir, dolutegravir, and lamivudine tablets in children with HIV (IMPAACT 2019): week 24 results of an open-label, multicentre, phase 1–2 dose-confirmation study
14. Long-Term Safety and Efficacy of Dolutegravir in Treatment-Experienced Adolescents With Human Immunodeficiency Virus Infection: Results of the IMPAACT P1093 Study
15. Pharmacokinetic variability of CFTR modulators from standard and alternative regimens
16. Quantitation of cystic fibrosis triple combination therapy, elexacaftor/tezacaftor/ivacaftor, in human plasma and cellular lysate
17. Elvitegravir/cobicistat pharmacokinetics in pregnant and postpartum women with HIV
18. The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies
19. Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093): results of an open-label, phase 1–2 trial
20. Routine use of low-dose glucarpidase following high-dose methotrexate in adult patients with CNS lymphoma: an open-label, multi-center phase I study
21. HIV-1 proviral landscapes distinguish posttreatment controllers from noncontrollers
22. Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV
23. Hemopexin reverses activation of lung eIF2α and decreases mitochondrial injury in chlorine-exposed mice.
24. Hemopexin Reverses Activation of Lung eIF2a and Decreases Mitochondrial Injury in Chlorine Exposed Mice
25. An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer
26. Transdermal Delivery of Enfuvirtide in a Porcine Model Using a Low-Frequency, Low-Power Ultrasound Transducer Patch
27. A dynamic Bayesian nonlinear mixed-effects model of HIV response incorporating medication adherence, drug resistance and covariates
28. Impact of Genetic Variants in ABCG2, NR1I2, and UGT1A1 on the Pharmacokinetics of Dolutegravir in Children.
29. Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized Trial
30. Nevirapine Exposure with WHO Pediatric Weight Band Dosing: Enhanced Therapeutic Concentrations Predicted Based on Extensive International Pharmacokinetic Experience
31. Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy
32. Impact of Low Birth Weight and Prematurity on Neonatal Raltegravir Pharmacokinetics: Impaact P1097
33. Raltegravir (RAL) in Neonates: Dosing, Pharmacokinetics (PK), and Safety in HIV-1–Exposed Neonates at Risk of Infection (IMPAACT P1110)
34. Use of Modeling and Simulations to Determine Raltegravir Dosing in Neonates: A Model for Safely and Efficiently Determining Appropriate Neonatal Dosing Regimens: IMPAACT P1110
35. Pharmacokinetics and safety of a raltegravir-containing regimen in HIV-infected children aged 2–12 years on rifampicin for tuberculosis
36. A Phase I/II Study of Preoperative Letrozole, Everolimus, and Carotuximab in Stage 2 and 3 Hormone Receptor-positive and Her2-negative Breast Cancer.
37. Plasma and cellular ivacaftor concentrations in patients with cystic fibrosis
38. A sensitive HPLC–MS/MS method for the determination of dolutegravir in human plasma
39. HIV RNA persists in rectal tissue despite rapid plasma virologic suppression with dolutegravir-based therapy
40. Monotypic low-level HIV viremias during antiretroviral therapy are associated with disproportionate production of X4 virions and systemic immune activation
41. Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events
42. Transplacental Transfer of Azithromycin and Its Use for Eradicating Intra-amniotic Ureaplasma Infection in a Primate Model
43. Pharmacokinetics, Safety, and 48-Week Efficacy of Oral Raltegravir in HIV-1-Infected Children Aged 2 Through 18 Years
44. Systemic Administration of a Brain Permeable Cdk5 Inhibitor Alters Neurobehavior
45. The impact of enzyme-inducing antiepileptic drugs on antiretroviral drug levels: A case-control study
46. Three Distinct Phases of HIV-1 RNA Decay in Treatment-Naive Patients Receiving Raltegravir-Based Antiretroviral Therapy: ACTG A5248
47. Clinical and Genetic Determinants of Plasma Nevirapine Exposure Following an Intrapartum Dose to Prevent Mother-to-Child HIV Transmission
48. Oseltamivir Pharmacokinetics, Dosing, and Resistance Among Children Aged <2 Years With Influenza
49. Oseltamivir Dosing in Premature Infants
50. Ivacaftor-elexacaftor-tezacaftor and tacrolimus combination in cystic fibrosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.